Table 2. Summary of results for the risk ratio (RR) of adverse effects in the cyclophosphamide arm compared to control arm.
| Outcomes | References | Participants | RR (95% CI), cyclophosphamide arm compared to control arm | P value | Heterogeneity | |
|---|---|---|---|---|---|---|
| P value | I2 (%) | |||||
| Anemia | (3) | 1,397 | 1.14 (0.35, 3.69) | 0.82 | 0.05 | 68 |
| Leucopenia | (2) | 1,848 | 3.43 (0.41, 28.43) | 0.25 | <0.001 | 100 |
| Neutropenia | (3) | 1,932 | 1.18 (0.46, 3.02) | 0.73 | <0.001 | 99 |
| Thrombocytopenia | (3) | 1,932 | 3.38 (1.96, 5.84) | <0.001 | 0.48 | 0 |
| Neutropenic fever | (2) | 1,029 | 0.41 (0.00, 62.18) | 0.73 | <0.001 | 96 |
| Alopecia | (3) | 1,932 | 1.01 (0.98, 1.04) | 0.66 | 0.48 | 0 |
| Infection | (2) | 1,848 | 0.57 (0.41, 0.79) | <0.001 | 0.90 | 0 |
| Fatigue | (2) | 1,848 | 1.06 (0.57, 1.97) | 0.86 | 0.004 | 88 |
| Sensory or motor neuropathy | (3) | 1,396 | 1.57 (1.03, 2.39) | 0.03 | 0.4 | 0 |
| Mucositis | (2) | 1,029 | 0.74 (0.47, 1.17) | 0.20 | 0.43 | 0 |
| Skin changes | (2) | 1,848 | 0.69 (0.06, 8.32) | 0.77 | <0.001 | 97 |
| Loss of appetite | (2) | 1,848 | 0.83 (0.62, 1.11) | 0.21 | 0.34 | 0 |
| Nausea or vomiting | (3) | 1,932 | 1.51 (1.11, 2.06) | 0.009 | 0.16 | 46 |
| Diarrhea | (3) | 1,932 | 0.46 (0.30, 0.68) | <0.001 | 0.75 | 0 |
| Stomatitis | (2) | 1,848 | 1.08 (0.29, 4.06) | 0.91 | 0.002 | 90 |
| Abnormal level of bilirubin | (2) | 1,029 | 0.30 (0.03, 2.82) | 0.29 | 0.92 | 0 |
| Abnormal level of AST | (2) | 1,029 | 1.86 (0.47, 7.35) | 0.38 | 0.87 | 0 |
| Abnormal level of ALT | (2) | 1,029 | 1.47 (0.34, 6.30) | 0.60 | 0.01 | 84 |
Italic P values indicate statistical significance. RR, risk ratio; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase.